The UK and US have agreed to a landmark trade agreement that will ensure no duties on UK pharmaceutical products being sold in the American market.
Agreement Details of the Deal
Under the terms of the agreement, the UK has committed to raise expenditure on medicines through the public health system. This move ensures that duties on these key goods will stay at zero for a duration of the next three years.
This deal follows earlier warnings to dramatically increase import taxes on patented pharmaceutical products, with figures floated as high as double the cost.
"This deal between the UK reinforces the international landscape for cutting-edge drugs and establishes much-needed equity to U.S.–U.K. pharmaceutical trade," a statement noted.
Economic Significance
Pharmaceuticals represent one of the Britain's biggest exports to the America, which is clearly the biggest buyer for major companies like GSK and AstraZeneca.
Export figures indicate that in the 12 months prior to the third quarter, the UK sold pharmaceutical products totaling over eleven billion pounds to the US. This figure accounted for 17.4% of all goods exports in that period.
"This agreement protects employment, increases funding and sets the stage for the UK to establish itself as a worldwide center for medical research," the Business and Trade Secretary remarked.
Detailed NHS Changes
The deal entails several notable changes from the United Kingdom:
- Revised Affordability Limit: The UK will raise the cost ceiling at which it deems new therapies to be unaffordable by 25%.
- Boosted Medicine Funding: There is a goal to double overall public funding on drugs from 0.3% of GDP to 0.6 percent over the next decade.
- Payback Limit: The sum pharmaceutical firms must pay back to the NHS to prevent overspending will be restricted at 15%. In the past, refunds exceeded twenty percent.
Industry Background
This agreement takes place against a ongoing row between the drug companies and the ministers over medicine costs and NHS adoption.
These tensions were intensified by claims that US consumers were paying significantly more for the identical medicines than consumers in the UK and Europe.
In recent months, several significant manufacturing plans in the UK have been halted or abandoned, while substantial investments have been pledged toward American operations.
A senior figure acknowledged that the NHS needed to spend more on drugs, noting that its expenditure on drugs had declined as a share of its resources over the last ten years.
